BNP Paribas Financial Markets Purchases New Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

BNP Paribas Financial Markets purchased a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 91,265 shares of the company's stock, valued at approximately $7,471,000. BNP Paribas Financial Markets owned about 0.07% of Vaxcyte as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also added to or reduced their stakes in PCVX. Nisa Investment Advisors LLC raised its position in Vaxcyte by 21.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,684 shares of the company's stock worth $220,000 after acquiring an additional 475 shares during the period. Avior Wealth Management LLC raised its position in Vaxcyte by 21.1% in the fourth quarter. Avior Wealth Management LLC now owns 6,456 shares of the company's stock worth $528,000 after acquiring an additional 1,124 shares during the period. Blue Trust Inc. raised its position in Vaxcyte by 125.1% in the fourth quarter. Blue Trust Inc. now owns 835 shares of the company's stock worth $68,000 after acquiring an additional 464 shares during the period. KBC Group NV raised its position in Vaxcyte by 78.0% in the fourth quarter. KBC Group NV now owns 4,775 shares of the company's stock worth $391,000 after acquiring an additional 2,092 shares during the period. Finally, Chicago Partners Investment Group LLC raised its position in shares of Vaxcyte by 9.2% in the fourth quarter. Chicago Partners Investment Group LLC now owns 5,431 shares of the company's stock valued at $440,000 after purchasing an additional 458 shares during the period. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the transaction, the chief operating officer now owns 154,931 shares of the company's stock, valued at $11,351,794.37. The trade was a 4.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 3.10% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on PCVX shares. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Needham & Company LLC reissued a "buy" rating and issued a $90.00 price target on shares of Vaxcyte in a research report on Tuesday, April 8th. Bank of America lowered their price target on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Cantor Fitzgerald started coverage on shares of Vaxcyte in a research report on Tuesday, April 22nd. They issued an "overweight" rating on the stock. Finally, The Goldman Sachs Group lowered their price target on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Vaxcyte presently has an average rating of "Buy" and an average target price of $136.50.

Vaxcyte Stock Up 3.1%

NASDAQ:PCVX traded up $0.95 during mid-day trading on Friday, hitting $31.85. 1,522,478 shares of the stock traded hands, compared to its average volume of 1,338,366. The business's 50-day moving average price is $42.56 and its 200 day moving average price is $71.47. The company has a market cap of $4.11 billion, a PE ratio of -6.92 and a beta of 1.27. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same period last year, the firm earned ($0.85) EPS. Analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.